Biopharma Daily Stock Updates - 01/11/21

Updated: Jan 13

$XBI $148.06 (-0.99%) 📉


COVID:

$HGEN (+7.61%) - Humanigen and EVERSANA Announce Partnership to Support the Launch and Commercialization of Lenzilumab for the Treatment of COVID-19

https://www.humanigen.com/press/Humanigen-and-EVERSANA-Announce-Partnership-to-Support-the-Launch-and-Commercialization-of-Lenzilumab-for-the-Treatment-of-COVID-19



FINANCIALS:

$HRTX (-1.83%) - Heron Therapeutics Highlights Progress in Pain Management and CINV Franchises and Announces New Development Program

https://herontherapeutics.gcs-web.com/news-releases/news-release-details/heron-therapeutics-highlights-progress-pain-management-and-1


$ZNGX (-3.44%) - Zogenix Announces Preliminary, Unaudited Fourth Quarter 2020 Net Product Sales

https://zogenixinc.gcs-web.com/news-releases/news-release-details/zogenix-announces-preliminary-unaudited-fourth-quarter-2020-net



PIPELINE:

$ADVM (+2.44%) - Adverum Biotechnologies Completes Patient Enrollment for INFINITY Phase 2 Trial of ADVM-022 in DME and Provides 2021 Business Outlook

https://investors.adverum.com/news-releases/news-release-details/adverum-biotechnologies-completes-patient-enrollment-infinity


$CARA (+2.63%) - Initiates Phase 2 Trial of Oral KORSUVA™ for the Treatment of Pruritus in Patients with Notalgia Paresthetica

http://ir.caratherapeutics.com/news-releases/news-release-details/cara-initiates-phase-2-trial-oral-korsuvatm-treatment-pruritus


CYTK (-7.19%) - CYTOKINETICS GRANTED ORPHAN DRUG DESIGNATION FOR CK-3773274 FOR THE TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY

https://ir.cytokinetics.com/news-releases/news-release-details/cytokinetics-granted-orphan-drug-designation-ck-3773274


$AERI (-1.07%) - Aerie Pharmaceuticals Receives European Commission Approval for Roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%

https://investors.aeriepharma.com/news-releases/news-release-details/aerie-pharmaceuticals-receives-european-commission-approval-0


$EDIT (-15.06%) - Editas Medicine Reports On Recent Progress And Outlook At J.P. Morgan Healthcare Conference & IND Acceptance

https://ir.editasmedicine.com/news-releases/news-release-details/editas-medicine-reports-recent-progress-and-outlook-jp-morgan


$ORIC (+1.66%) - ORIC Pharmaceuticals Provides Corporate Update and Highlights Key 2021 Milestones

https://investors.oricpharma.com/news-releases/news-release-details/oric-pharmaceuticals-provides-corporate-update-and-highlights


$APVO (-3.31%) - Aptevo Therapeutics Provides Update on Ongoing APVO436 Phase 1 Clinical Trial

https://aptevotherapeutics.gcs-web.com/news-releases/news-release-details/aptevo-therapeutics-provides-update-ongoing-apvo436-phase-1-1


$INFI (+8.16%) - Infinity Pharmaceuticals Announces MARIO-275 Phase 2 Data in Patients with Advanced Urothelial Cancer to be Presented at ASCO Genitourinary Cancers Symposium

https://investors.infi.com/news-releases/news-release-details/infinity-pharmaceuticals-announces-mario-275-phase-2-data


$MGTA (+2.26%) - Magenta Therapeutics Highlights Recent Progress and Expected Timing of 2021 Milestones, Including Four Ongoing and Planned Clinical Trials

https://investor.magentatx.com/news-releases/news-release-details/magenta-therapeutics-highlights-recent-progress-and-expected


$ORTX (-6.28%) - Orchard Therapeutics Announces 2021 Corporate Priorities Supporting the Build-out of its Commercial Business in Hematopoietic Stem Cell (HSC) Gene Therapy and Expansion of its Clinical Applications

https://ir.orchard-tx.com/news-releases/news-release-details/orchard-therapeutics-announces-2021-corporate-priorities


$WVE (-6.96%) - Wave Life Sciences Highlights Pipeline Progress and Expansion Leveraging New PN Backbone Chemistry Modifications

https://ir.wavelifesciences.com/news-releases/news-release-details/wave-life-sciences-highlights-pipeline-progress-and-expansion



0 comments